THOMAS WHEELER to Genetic Vectors
This is a "connection" page, showing publications THOMAS WHEELER has written about Genetic Vectors.
Connection Strength
0.086
-
Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology. 1997 Feb; 49(2):173-80.
Score: 0.025
-
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
Score: 0.017
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.010
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
Score: 0.009
-
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
Score: 0.009
-
In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
Score: 0.008
-
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49.
Score: 0.007